Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Journal of Alzheimer'S Disease : JAD
|
November 22, 2021
Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer's Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
Nicolas R Barthélemy, Balazs Toth, Paul T Manser, et al.
American Journal of Veterinary Research
|
November 27, 2012
Evaluation of squeeze-induced somnolence in neonatal foals
Balazs Toth, Monica Aleman, Robert J Brosnan, et al.
Brain : a Journal of Neurology
|
May 28, 2025
CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures
Alyaa M Abdel-Haleem, Ellen Casavant, Balazs Toth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
October 6, 2024
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab
Cosme Sandoval, Julie Lee, Balazs Toth, et al.
Cell
|
May 2, 2006
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling
Zachary A Knight, Beatriz Gonzalez, Morri E Feldman, et al.
Neurology
|
August 29, 2023
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
Cecilia Monteiro, Balazs Toth, Flavia Brunstein, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 10, 2020
Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)
Stanley Cohen, Katie Tuckwell, Tamiko R Katsumoto, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 8, 2024
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology
Stephen P Schauer, Balazs Toth, Julie Lee, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
June 29, 2026
Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease
Julie Lee, Emily Olafson, Balazs Toth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Julie Lee, Balazs Toth, Sandra Sanabria Bohorquez, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Journal of Alzheimer'S Disease : JAD
|
November 22, 2021
Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer's Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
Nicolas R Barthélemy, Balazs Toth, Paul T Manser, et al.
American Journal of Veterinary Research
|
November 27, 2012
Evaluation of squeeze-induced somnolence in neonatal foals
Balazs Toth, Monica Aleman, Robert J Brosnan, et al.
Brain : a Journal of Neurology
|
May 28, 2025
CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures
Alyaa M Abdel-Haleem, Ellen Casavant, Balazs Toth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
October 6, 2024
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab
Cosme Sandoval, Julie Lee, Balazs Toth, et al.
Cell
|
May 2, 2006
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling
Zachary A Knight, Beatriz Gonzalez, Morri E Feldman, et al.
Neurology
|
August 29, 2023
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
Cecilia Monteiro, Balazs Toth, Flavia Brunstein, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 10, 2020
Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)
Stanley Cohen, Katie Tuckwell, Tamiko R Katsumoto, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 8, 2024
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology
Stephen P Schauer, Balazs Toth, Julie Lee, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
June 29, 2026
Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease
Julie Lee, Emily Olafson, Balazs Toth, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Julie Lee, Balazs Toth, Sandra Sanabria Bohorquez, et al.
Page
of 5